Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Antonio Russo, Giuseppe Bronte, Giovanni Sortino, Marta Castiglia, Francesco Passiglia, Christian Rolfo, Luis Raez, Evelien Smits, Edgardo S Santos, Marta Castiglia, Francesco Passiglia, Annelies Janssens, Patrick Pauwels

Risultato della ricerca: Article

19 Citazioni (Scopus)

Abstract

Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent 'cancer immunoediting' has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.
Lingua originaleEnglish
pagine (da-a)1173-1187
Numero di pagine15
RivistaExpert Review of Anticancer Therapy
Volume14
Stato di pubblicazionePublished - 2014

Fingerprint

Immunotherapy
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Therapeutics
Cancer Vaccines
Subunit Vaccines
Neoplasms
Monoclonal Antibodies
Clinical Trials
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cita questo

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? / Russo, Antonio; Bronte, Giuseppe; Sortino, Giovanni; Castiglia, Marta; Passiglia, Francesco; Rolfo, Christian; Raez, Luis; Smits, Evelien; Santos, Edgardo S; Castiglia, Marta; Passiglia, Francesco; Janssens, Annelies; Pauwels, Patrick.

In: Expert Review of Anticancer Therapy, Vol. 14, 2014, pag. 1173-1187.

Risultato della ricerca: Article

Russo, A, Bronte, G, Sortino, G, Castiglia, M, Passiglia, F, Rolfo, C, Raez, L, Smits, E, Santos, ES, Castiglia, M, Passiglia, F, Janssens, A & Pauwels, P 2014, 'Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?', Expert Review of Anticancer Therapy, vol. 14, pagg. 1173-1187.
Russo, Antonio ; Bronte, Giuseppe ; Sortino, Giovanni ; Castiglia, Marta ; Passiglia, Francesco ; Rolfo, Christian ; Raez, Luis ; Smits, Evelien ; Santos, Edgardo S ; Castiglia, Marta ; Passiglia, Francesco ; Janssens, Annelies ; Pauwels, Patrick. / Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. In: Expert Review of Anticancer Therapy. 2014 ; Vol. 14. pagg. 1173-1187.
@article{6a183dd25d1048248523a20c637f0031,
title = "Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?",
abstract = "Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent 'cancer immunoediting' has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.",
author = "Antonio Russo and Giuseppe Bronte and Giovanni Sortino and Marta Castiglia and Francesco Passiglia and Christian Rolfo and Luis Raez and Evelien Smits and Santos, {Edgardo S} and Marta Castiglia and Francesco Passiglia and Annelies Janssens and Patrick Pauwels",
year = "2014",
language = "English",
volume = "14",
pages = "1173--1187",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

AU - Russo, Antonio

AU - Bronte, Giuseppe

AU - Sortino, Giovanni

AU - Castiglia, Marta

AU - Passiglia, Francesco

AU - Rolfo, Christian

AU - Raez, Luis

AU - Smits, Evelien

AU - Santos, Edgardo S

AU - Castiglia, Marta

AU - Passiglia, Francesco

AU - Janssens, Annelies

AU - Pauwels, Patrick

PY - 2014

Y1 - 2014

N2 - Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent 'cancer immunoediting' has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.

AB - Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent 'cancer immunoediting' has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.

UR - http://hdl.handle.net/10447/112723

M3 - Article

VL - 14

SP - 1173

EP - 1187

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

ER -